Purcell & Lefkowitz LLP is investigating Abeona Therapeutics Inc. on behalf of its shareholders to determine if the company's directors breached their fiduciary duties related to recent corporate actions. This probe could impact shareholder rights and the company's governance. Shareholders interested in their options can contact the law firm for more information and legal assistance at no cost or obligation. The investigation highlights concerns about potential corporate misconduct affecting investor interests.
Industrial Alliance Securities lowered Abeona Therapeutics' price target from $20 to $15 following a 14% stock drop after the company reported Q2 revenues of $11.4 million, missing analyst expectations. The company faces operational challenges with i...
Abeona Therapeutics reported Q2 revenues of $11.4 million, falling short of analyst expectations and causing a 14% drop in its stock price. The company treated five patients with its drug Zevaskyn for recessive dystrophic epidermolysis bullosa but fa...
